ProjectBI 1516-0003 – a phase Ib, multicentre, randomised, double-blind, placebo-controlled 2 sequence crossover trial to…

Basic data

Acronym:
BI 1516-0003
Title:
a phase Ib, multicentre, randomised, double-blind, placebo-controlled 2 sequence crossover trial to evaluate the effects of BI 3031185 on safety, tolerability, pharmacodynamics, and pharmacokinetics in patients with borderline personality disorder (BPD) or attention-deficit/hyperactivity disorder (ADHD)
Duration:
15/07/2025 to 31/12/2026
Abstract / short description:
the main objective of the trial is to assess safety and tolerability of a single dose of BI 3031185 in participants with BPD or ADHD

Involved staff

Managers

Faculty of Medicine
University of Tübingen
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine

Other staff

Department of Psychology
Faculty of Science
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes
Faculty of Medicine

Funders

Ingelheim am Rhein, Rheinland-Pfalz, Germany
Help

will be deleted permanently. This cannot be undone.